430 related articles for article (PubMed ID: 2429858)
1. Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies.
Christensson-Nylander I; Herrera-Marschitz M; Staines W; Hökfelt T; Terenius L; Ungerstedt U; Cuello C; Oertel WH; Goldstein M
Exp Brain Res; 1986; 64(1):169-92. PubMed ID: 2429858
[TBL] [Abstract][Full Text] [Related]
2. Striato-nigral dynorphin and substance P pathways in the rat. II. Functional analysis.
Herrera-Marschitz M; Christensson-Nylander I; Sharp T; Staines W; Reid M; Hökfelt T; Terenius L; Ungerstedt U
Exp Brain Res; 1986; 64(1):193-207. PubMed ID: 2429859
[TBL] [Abstract][Full Text] [Related]
3. Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms.
Reid MS; Herrera-Marschitz M; Hökfelt T; Lindefors N; Persson H; Ungerstedt U
Exp Brain Res; 1990; 82(2):293-303. PubMed ID: 1704847
[TBL] [Abstract][Full Text] [Related]
4. Dopamine receptors mediate alterations in striato-nigral dynorphin and substance P pathways.
Nylander I; Terenius LH
Neuropharmacology; 1987 Sep; 26(9):1295-302. PubMed ID: 2444900
[TBL] [Abstract][Full Text] [Related]
5. The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis--I. Effects of K(+)-depolarization, lesions and peptidase inhibition.
You ZB; Nylander I; Herrera-Marschitz M; O'Connor WT; Goiny M; Terenius L
Neuroscience; 1994 Nov; 63(2):415-25. PubMed ID: 7891855
[TBL] [Abstract][Full Text] [Related]
6. Topographic projections of substance P and GABA pathways in the striato- and pallido-nigral system: a biochemical and immunohistochemical study.
Jessell TM; Emson PC; Paxinos G; Cuello AC
Brain Res; 1978 Sep; 152(3):487-98. PubMed ID: 356929
[TBL] [Abstract][Full Text] [Related]
7. The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis--II. Effects of dopamine D1 and D2 receptor agonists.
You ZB; Herrera-Marschitz M; Nylander I; Goiny M; O'Connor WT; Ungerstedt U; Terenius L
Neuroscience; 1994 Nov; 63(2):427-34. PubMed ID: 7891856
[TBL] [Abstract][Full Text] [Related]
8. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.
Engber TM; Susel Z; Kuo S; Gerfen CR; Chase TN
Brain Res; 1991 Jun; 552(1):113-8. PubMed ID: 1717109
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical evidence for a neurotensin striatonigral pathway in the rat brain.
Castel MN; Morino P; Frey P; Terenius L; Hökfelt T
Neuroscience; 1993 Aug; 55(3):833-47. PubMed ID: 8105419
[TBL] [Abstract][Full Text] [Related]
10. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis.
Gerfen CR; McGinty JF; Young WS
J Neurosci; 1991 Apr; 11(4):1016-31. PubMed ID: 1707092
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical demonstration of differential substance P-, met-enkephalin-, and glutamic-acid-decarboxylase-containing cell body and axon distributions in the corpus striatum of the cat.
Beckstead RM; Kersey KS
J Comp Neurol; 1985 Feb; 232(4):481-98. PubMed ID: 2579980
[TBL] [Abstract][Full Text] [Related]
12. Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra.
Quirion R; Gaudreau P; Martel JC; St-Pierre S; Zamir N
Brain Res; 1985 Apr; 331(2):358-62. PubMed ID: 2859094
[TBL] [Abstract][Full Text] [Related]
13. Loss of substance P and enkephalin immunoreactivity in the human substantia nigra after striato-pallidal infarction.
Pioro EP; Hughes JT; Cuello AC
Brain Res; 1984 Feb; 292(2):339-47. PubMed ID: 6198046
[TBL] [Abstract][Full Text] [Related]
14. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans.
Reiner A; Medina L; Haber SN
Neuroscience; 1999; 88(3):775-93. PubMed ID: 10363817
[TBL] [Abstract][Full Text] [Related]
15. Compartmental distribution of ventral striatal neurons projecting to the mesencephalon in the rat.
Berendse HW; Groenewegen HJ; Lohman AH
J Neurosci; 1992 Jun; 12(6):2079-103. PubMed ID: 1607929
[TBL] [Abstract][Full Text] [Related]
16. Neuropeptides in striato-nigral pathways.
Cuello AC; Del Fiacco M; Paxinos G; Somogyi P; Priestley JV
J Neural Transm; 1981; 51(1-2):83-96. PubMed ID: 6167672
[TBL] [Abstract][Full Text] [Related]
17. Effects of BDNF and NT-4/5 on striatonigral neuropeptides or nigral GABA neurons in vivo.
Arenas E; Akerud P; Wong V; Boylan C; Persson H; Lindsay RM; Altar CA
Eur J Neurosci; 1996 Aug; 8(8):1707-17. PubMed ID: 8921261
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of glutamic acid decarboxylase mRNA in rat substantia nigra after an ibotenic acid lesion in the caudate-putamen.
Lindefors N; Brené S; Persson H
Brain Res Mol Brain Res; 1990 Apr; 7(3):207-12. PubMed ID: 2159580
[TBL] [Abstract][Full Text] [Related]
19. Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: regional and receptor specificity.
You ZB; Herrera-Marschitz M; Pettersson E; Nylander I; Goiny M; Shou HZ; Kehr J; Godukhin O; Hökfelt T; Terenius L; Ungerstedt U
Neuroscience; 1996 Oct; 74(3):793-804. PubMed ID: 8884775
[TBL] [Abstract][Full Text] [Related]
20. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.
Lapchak PA; Miller PJ; Collins F; Jiao S
Neuroscience; 1997 May; 78(1):61-72. PubMed ID: 9135089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
